Kalkine Media ASX Share Market News & Research
Watchlist Sign Up/Login
https://kalkinemedia.com/resources/assets/public/img/flags/au.png AUS
https://kalkinemedia.com/resources/assets/public/img/flags/nz.png NZ
https://kalkinemedia.com/resources/assets/public/img/flags/uk.png UK
https://kalkinemedia.com/resources/assets/public/img/flags/ca.png CA
https://kalkinemedia.com/resources/assets/public/img/flags/us.png USA
https://kalkinemedia.com/resources/assets/public/img/flags/fr.png FRA
https://kalkinemedia.com/resources/assets/public/img/flags/de.png GER
https://kalkinemedia.com/resources/assets/public/img/flags/es.png ESP
https://kalkinemedia.com/resources/assets/public/img/flags/it.png ITA
https://kalkinemedia.com/resources/assets/public/img/flags/nl.png NLD
https://kalkinemedia.com/resources/assets/public/img/flags/pt.png PRT
https://kalkinemedia.com/resources/assets/public/img/flags/se.png SWE
https://kalkinemedia.com/resources/assets/public/img/flags/gr.png GRC
https://kalkinemedia.com/resources/assets/public/img/flags/in.png IND
https://kalkinemedia.com/resources/assets/public/img/flags/pl.png POL
https://kalkinemedia.com/resources/assets/public/img/flags/br.png BRA
https://kalkinemedia.com/resources/assets/public/img/flags/za.png ZAF
https://kalkinemedia.com/resources/assets/public/img/flags/ru.png RUS
https://kalkinemedia.com/resources/assets/public/img/flags/cn.png CHN
https://kalkinemedia.com/resources/assets/public/img/flags/ae.png UAE
Kalkine Media ASX Share Market News & Research

Biocell Ltd Granted EU Patent for OBX - Novel breast cancer risk reduction and therapy drug candidate

February 24, 2025 11:33 PM IST | By EIN Presswire
Biocell Ltd Granted EU Patent for OBX - Novel breast cancer risk reduction and therapy drug candidate
Image source: EIN Presswire

Recent News

thumbnail

AI Meets Expertise: Uniqus and Numeric Join Forces to Transform the Fi...

thumbnail

Groups Representing Patients, Healthcare Professionals and Pharmaceuti...

thumbnail

ExaGrid Expands Partnership with Cohesity with New Certified Integrati...

thumbnail

Introducing MiQ Sigma: Built at MiQ’s Bengaluru Centre of Excellence (...

Breast health care for the 21st century. Hacking cellular pathways to rewrite our cancer odds and disrupting cancer before it starts. Dr Kevehazi, Biocell CEO

Disrupting Breast Cancer Before It Starts: Our Proactive Battleplan - Hacking Cellular Health to Rewrite Our Cancer Odds”
— Laura Mann Kevehazi, DMD, FRSM founder of Biocell
LONDON, UNITED KINGDOM, February 24, 2025 /EINPresswire.com/ -- Biocell Ltd announces it has been granted an EU patent for its novel development in breast cancer prevention for women of all ages. “Rewriting the breast cancer odds and blocking breast malignancy development before it starts is the future of women’s health” said Biocell founder Dr Kevehazi.

The patented formula is a novel versatile therapeutic and chemo-preventive effective against both ER+, representing 80% of breast cancer cases and Triple-Negative Breast Cancer (TNBC) cells as well as additional high unmet need solid tumor. It can be taken by women starting in their 20 for breast cancer risk reduction.

The company also has additional patents pending in the Japan, Mexico, and Canada, following positive patentability report from World International Patent Organization - WIPO.

Two decades ago, when Biocell founder Dr Laura Mann Kevehazi DMD began early screening for breast cancer due to high-risk family history, a question kept coming up: why are we sitting ducks waiting to discover breast tumors instead of safely targeting disease at the source, disrupting cancer before it starts in our breast tissue?

"The future of breast cancer care is prevention. All women deserve breast healthcare for the 21st Century, the patented OBX offers the pro-active choice to significantly and safely lower their breast cancer risk," said Dr. Kevehazi.

Breast cancer cases are increasing globally, with newly diagnosed cases projected to grow 40% by 2040. The Breast Cancer Therapeutics Market size reached USD 28.8 billion in 2022 and is projected to reach USD 73.68 billion by 2032, with a compound annual growth rate (CAGR) of 9.9%.

Biocell Ltd is actively seeking exclusive licensing partnerships for the US, EU, Japan and Mexico markets.

About Biocell Ltd:
Biocell Ltd is a UK-based biotech company developing innovative solutions for cancer prevention and treatment. For more information, visit www.biocellhealth.co.uk

Laura Mann Kevehazi
BIOCELL LTD
+44 7504 947099
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Sponsored Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.